title: Detection of portal perfusion abnormalities: comparison of 3 ferucarbotran-enhanced magnetic resonance imaging sequences.
abstract: OBJECTIVE
  To estimate the accuracy, sensitivity, and specificity of 3 ferucarbotran-enhanced magnetic resonance (MR) imaging sequences prospectively for the detection of nontumoral portal perfusion abnormalities.
  
  
  METHODS
  Thirty-nine noncirrhotic patients with liver metastases underwent computed tomography during arterial portography (CTAP) and MR imaging comprising T1-weighted gradient recalled echo (GRE), T2-weighted fast spin echo (FSE), and T2*-weighted GRE sequences with and without ferucarbotran. Magnetic resonance images were reviewed by 4 blinded observers for rating based on the confidence scale. The accuracy, sensitivity, and specificity for each sequence were measured by receiver operating characteristic analysis. Contrast-to-noise ratio (CNR) and relative signal-to-noise ratio changes were statistically compared.
  
  
  RESULTS
  Thirty-nine nontumoral perfusion defects were observed in 22 patients by CTAP. Receiver operating characteristic analysis showed the accuracy was higher for T2*-weighted GRE (0.884) than for T1-weighted GRE (0.572) and T2-weighted FSE (0.597). T2*-weighted imaging achieved the highest sensitivity (81.4%) and the lowest specificity (86.6%). Postenhanced T2*-weighted imaging achieved the highest CNR (19.3 +/- 9.2).
  
  
  CONCLUSIONS
  T2*-weighted imaging was the most accurate and sensitive method for detecting portal perfusion abnormalities compared with T1- or T2-weighted imaging, whereas T1- or T2-weighted imaging is superior in specificity to T2*-weighted imaging during ferucarbotran-enhanced MR imaging.
authors.affiliation: Department of Radiology, Osaka City University Graduate School of Medicine, Osaka, Japan. cxr@med.osaka-cu.ac.jp
authors.forename: Jin
authors.initials: J
authors.lastname: Iwazawa
authors.forename: Norifumi
authors.initials: N
authors.lastname: Nishida
authors.forename: Akira
authors.initials: A
authors.lastname: Yamamoto
authors.forename: Mineyoshi
authors.initials: M
authors.lastname: Nango
authors.forename: Teruhisa
authors.initials: T
authors.lastname: Ninoi
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Murakami
authors.forename: Kenji
authors.initials: K
authors.lastname: Nakamura
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Inoue
mesh_terms: D003287:Contrast Media; D003911:Dextrans; D052203:Ferrosoferric Oxide; D006801:Humans; D007501:Iron; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000556:secondary*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D058185:Magnetite Nanoparticles; D010087:Oxides; D011168:Portal System; D011172:Portography; D011446:Prospective Studies; D012372:ROC Curve; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; D007501:Iron; C065507:ferumoxides; D052203:Ferrosoferric Oxide